Tesamorelin

Description

Introduction to Tesamorelin (Research Use Only)

Tesamorelin is a synthetic peptide composed of six amino acids:
His-D-Ala-Trp-D-Phe-Lys-NH₂.

It is designed to act as a growth hormone-releasing hormone (GHRH) analog, meaning it mimics the natural GHRH secreted by the hypothalamus. By binding to GHRH receptors in the anterior pituitary gland, Tesamorelin stimulates the endogenous release of growth hormone (GH). It is of particular interest in research focused on metabolism, aging, cognitive function, and body composition.

Key Areas of Study

1. Visceral Fat and Body Composition

Tesamorelin has been studied extensively in models of visceral adipose tissue (VAT) accumulation. It is FDA-approved for HIV-associated lipodystrophy, and research continues to explore its broader effects on abdominal fat metabolism and redistribution.

2. Lipid Metabolism and Cardiovascular Markers

Preclinical and clinical studies have reported improvements in lipid profiles, including reduced triglyceride levels and increased HDL cholesterol. These changes are of interest in cardiovascular disease risk reduction models.

3. Cognitive and Neurological Function

Recent studies have evaluated Tesamorelin’s impact on cognitive domains, particularly in relation to executive function and memory. Its influence on GH/IGF-1 pathways may support synaptic plasticity and neuronal survival in aging and neurodegeneration models.

4. Muscle Anabolism

Tesamorelin’s ability to stimulate GH release is associated with downstream increases in IGF-1, which is essential for muscle protein synthesis. Research includes models of sarcopenia and anabolic resistance in older populations.

5. Skin Structure and Elasticity

GH is known to influence collagen production and dermal thickness. Tesamorelin’s GH-promoting action has been studied in the context of skin regeneration and age-related dermal thinning.

6. Bone Density and Structural Integrity

Through its effect on IGF-1 production, Tesamorelin may support osteoblast activity and bone remodeling. It is being evaluated in bone health models, especially in the context of aging and osteoporosis risk.

7. Energy Metabolism

Tesamorelin is associated with enhanced mitochondrial function and basal metabolic rate via its GH-releasing action. These effects are under study in models of metabolic dysfunction, energy expenditure, and glucose regulation.

8. Inflammatory Modulation

Research suggests Tesamorelin may influence systemic inflammation, with observed changes in inflammatory biomarkers in clinical populations. This has led to interest in its use in models related to metabolic syndrome and chronic inflammatory conditions.

9. Sleep and Circadian Biology

Because GH release is closely tied to slow-wave sleep, Tesamorelin’s action on the somatotropic axis may positively influence sleep architecture and recovery processes, particularly in older or GH-deficient populations.

10. Immune System Research

GH has known immunomodulatory effects, and Tesamorelin is being investigated for its role in supporting immune homeostasis, including lymphocyte development and cytokine regulation.

Supporting References (Scientific and Medical Journals)

• Fahy, G. M. et al. (2019). Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell, 18(6), e13028. https://doi.org/10.1111/acel.13028
• Guaraldi, G. et al. (2013). Tesamorelin reduces visceral fat and improves lipid profiles in HIV-infected patients with lipodystrophy. Journal of Clinical Endocrinology & Metabolism, 98(2), 604–610. https://doi.org/10.1210/jc.2012-3063
• Stanley, T. L. et al. (2016). Effects of tesamorelin on neurocognitive function in HIV-infected individuals. Clinical Infectious Diseases, 62(10), 1291–1297. https://doi.org/10.1093/cid/ciw112
• Tobias, J. H. et al. (2008). GH and IGF-1 signaling in muscle and bone: links to aging and sarcopenia. Journal of Endocrinology, 198(3), 367–382. https://doi.org/10.1677/JOE-08-0089
• Allard, J. P. et al. (2012). Tesamorelin therapy improves inflammatory markers and metabolic parameters. HIV Medicine, 13(6), 324–331. https://doi.org/10.1111/j.1468-1293.2011.00977.x

Disclaimer:
Tesamorelin is a research peptide and is not approved by the FDA for general human consumption or off-label therapeutic use. It is intended strictly for laboratory research purposes only. Any discussion of effects is based on animal studies and specific clinical research models, and does not imply human efficacy or safety. This product is not intended to diagnose, treat, cure, or prevent any disease.